Novagold Resources Inc. vs Twist Bioscience Corp — how do they compare? Novagold Resources Inc. trades at $6.32 (market cap $2.90B), while Twist Bioscience Corp trades at $146.73 (market cap $10.03B). The key difference: Twist Bioscience Corp is far larger — about 3.5× Novagold Resources Inc.'s market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Novagold Resources Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novagold Resources Inc. for 0 Days and Twist Bioscience Corp for 27 Days on average.
| NG | TWST | |
|---|---|---|
Market Cap | $2.90B | $10.03B |
Volume | 3,973,464 | 1,528,940 |
Sector | Basic Materials | Health |
52-Week High | $14.20 | $205.00 |
52-Week Low | $5.18 | $25.45 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $2.74B | $9.96B |
Signals from Pluang's Aura AI — not financial advice
NovaGold Resources (NG) trades at $6.63, down 1.49% today, as the company navigates its development phase for the Donlin Gold project. The stock shows mixed earnings performance with recent quarterly losses but beats expectations in two of the last four quarters. Financials reveal negative profitability metrics with ROE at -32.81% and net income of -$94.66M for 2025, though cash flow remains positive due to financing activities. Recent news highlights the company's move to acquire full ownership of Donlin Gold, a major Alaska gold project.
The outlook for NG hinges on successful development of Donlin Gold, with 100% analyst buy ratings signaling strong Wall Street confidence. However, significant execution risks exist given negative earnings and substantial capital requirements. Investors face volatility from gold price fluctuations and project development timelines, making this suitable for those with high risk tolerance seeking exposure to a major gold development story.
TWST trades at $148.16, down 2.44% today, with a bullish technical signal but negative earnings trends. Recent news highlights its role in Eli Lilly's AI drug discovery platform, driving investor optimism. Revenue growth is strong, reaching $376.57M in 2025, but net losses persist, with a margin of -20.63%. The stock faces resistance near $154, with support at $146.
Outlook is mixed: analyst consensus is bullish with a $153.70 price target, but profitability challenges and cash flow deficits pose risks. The AI collaboration offers growth potential, yet execution and margin improvement are critical for sustained upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
NovaGold Resources Inc. is a mineral exploration and development company that holds a majority interest in the Donlin Gold project, an undeveloped gold deposit in Alaska.
Read more on NG →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →